Parexel boosts RWD network via HealthVerity partnership

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Tetiana Lazunova)
(Image: Getty/Tetiana Lazunova)

Related tags Real world data RWD Parexel HealthVerity

Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.

Partner companies, such as Parexel, can browse, discover, and license data within HealthVerity’s self-service cloud platform, HealthVerity Marketplace, explained the company’s co-founder and CEO Andrew Kress.

“The real benefit for organizations is the power to link existing datasets within an enterprise to 60 major data sources,”​ he told us. This includes claims, lab results, biomarkers, device, electronic medical records (EMRs) in addition to grocery and consumer data.

While linking and de-identifying health care data is not new, HealthVerity approaches it ‘a bit differently’ – and 10-times more accurately than the industry average, said Kress.

“Linking health care data with consumer data and media impressions, in a HIPAA-compliant manner, has not been possible until now,”​ he said.

“HealthVerity leverages probabilistic matching technology to unite disparate patient records with a unique and persistent ID (HVID) that remains consistent across disparate data sources – not only within their data but across every partner in the ecosystem that’s using our software,”​ explained Kress.

Speaking to the recently announced strategic partnership, Kress said Parexel was looking to build customized RWD solutions to help its customers solve their complex clinical trial needs.

“Clinical trials are incredibly expensive, so increased access to interoperable data can only aid in the research and development of new therapies for patients,”​ he added.

According to HealthVerity, its technology is currently used by more than 100 health care organizations.

To support its expanding customer base, the Philadelphia, PA-headquartered company in April of this year closed a $25m Series C funding round, led by existing investor Foresite Capital with participation from Flare Capital Partners, Greycroft Partners, and other existing investors.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us

Products

View more

Webinars